Description
Wedica is a once-weekly dipeptidyl peptidase-IV (DPP-4) inhibitor designed to manage blood glucose levels effectively. By selectively and consistently inhibiting DPP-4, an enzyme responsible for inactivating incretin hormones such as glucagon-like peptide-1 and glucagon-dependent insulinotropic polypeptide, Wedica plays a crucial role in blood glucose regulation. This inhibition boosts insulin secretion proportionate to blood glucose levels, thereby aiding in controlling blood glucose levels. Wedica is conveniently available in tablet form for oral administration.
